```html

Xerosis of the Hands and Feet (Keratoderma)

Overview

Xerosis refers to abnormal dryness of the skin. When it involves the palms of the hands and/or the soles of the feet, it is often termed palmar‑plantar keratoderma or simply keratoderma. The condition is characterized by thickened, rough, and sometimes fissured skin that may be hyper‑keratotic (excess keratin) and scaly.

It can be primary (genetic or idiopathic) or secondary to systemic diseases, infections, medications, or environmental factors. Both men and women are affected, but some hereditary forms follow an X‑linked or autosomal‑dominant pattern that tends to be more common in men.

Exact prevalence is difficult to determine because many cases are mild and go unreported. However, epidemiological studies estimate that up to 5% of the general adult population experience clinically significant palmar‑plantar xerosis at some point in life, with higher rates (≈10–12%) among older adults (>65 years) and those with underlying dermatologic or metabolic disorders.<sup>1</sup>

Symptoms

The clinical presentation can vary from subtle dryness to painful hyper‑keratotic plaques. Common symptoms include:

• Dry, scaly skin on the palms and/or soles.
• Thickened (hyper‑keratotic) plaques that feel rough to the touch.
• Fissures or cracks especially in weight‑bearing areas (heel, metatarsal heads).
• Itching (pruritus) or a burning sensation.
• Pain or tenderness when walking or gripping objects.
• Hyperhidrosis (excessive sweating) may coexist, worsening maceration.
• Color changes – plaques may appear yellow‑brown, erythematous, or whitish.
• Blistering or ulceration in severe cases, especially if fissures become secondarily infected.

Causes and Risk Factors

Keratoderma is a heterogeneous condition. The most common categories are:

Primary (Genetic) Causes

• Inherited keratodermas – e.g., Vohwinkel syndrome, Mal de Meleda, epidermolytic palmoplantar keratoderma. These follow autosomal‑dominant, autosomal‑recessive, or X‑linked inheritance.
• Idiopathic xerosis – no identifiable trigger; often linked to age‑related decline in skin barrier lipids.

Secondary Causes

• Systemic diseases – psoriasis, eczema, ichthyosis, diabetes mellitus, hypothyroidism, chronic kidney disease, and HIV infection.
• Infections – fungal (tinea pedis, tinea manuum), bacterial (Staphylococcus aureus), or viral (HPV warts).
• Medications – retinoids, long‑term systemic corticosteroids, antimalarials, and some chemotherapeutic agents.
• Occupational & environmental exposure – repeated friction, manual labor, frequent hand‑washing, exposure to detergents, solvents, or extreme temperatures.
• Nutritional deficiencies – vitamin A, essential fatty acids, zinc.
• Aging – reduced sebaceous and sweat gland activity, decreased natural moisturizers.

Risk Factors

• Family history of keratoderma.
• Chronic exposure to water or irritants (e.g., healthcare workers, dishwashers).
• Underlying dermatologic or metabolic disease.
• Age >50 years.
• Male sex (particularly for X‑linked forms).

Diagnosis

Diagnosis is primarily clinical, based on history and physical examination. The steps include:

1. Detailed medical history – onset, progression, occupational exposure, family history, associated systemic symptoms.
2. Physical examination – visual inspection of the palms/soles, assessment of texture, distribution, presence of fissures or infection.
3. Dermatologic tools – Wood’s lamp (detects fungal fluorescence), dermoscopy (identifies characteristic patterns).
4. Laboratory tests (when secondary cause suspected):
   • Complete blood count, fasting glucose, HbA1c (diabetes screening).
   • Thyroid‑stimulating hormone (TSH) and free T4 (hypothyroidism).
   • Renal function panel (for chronic kidney disease).
   • Serology for HIV if risk factors present.
5. Skin biopsy – reserved for atypical presentations or to rule out psoriasis, lichen planus, or neoplastic processes. Histology typically shows hyperkeratosis, acanthosis, and sometimes eccrine duct abnormalities.
6. Microbiologic cultures – KOH preparation or fungal culture for suspected tinea; bacterial swab if secondary infection is evident.

Treatment Options

Treatment aims to restore the skin barrier, reduce hyperkeratosis, relieve symptoms, and address any underlying cause.

Topical Therapies

• Emollients & moisturizers – thick ointments (e.g., petrolatum, mineral oil, urea 10–20%) applied 2–3 times daily; “wet‑wrap” method enhances absorption.
• Keratinolytic agents – salicylic acid 2–5% or lactic acid creams to soften plaques.
• Topical corticosteroids – low‑ to medium‑potency (hydrocortisone 1%–0.5% clobetasol propionate for short courses) to control inflammation and itching.
• Topical retinoids – tretinoin 0.025–0.05% or adapalene; effective in reducing hyperkeratosis but may cause irritation.
• Calcineurin inhibitors – tacrolimus 0.03% or pimecrolimus 1% for patients who cannot tolerate steroids.

Systemic Medications

• Oral retinoids – acitretin (25–50 mg/day) is the mainstay for severe hereditary keratoderma; requires monitoring for hepatotoxicity and teratogenicity.
• Antifungals – oral terbinafine or itraconazole when a fungal infection contributes to xerosis.
• Systemic immunomodulators – methotrexate, cyclosporine, or biologics (e.g., secukinumab) in cases overlapping with psoriasis.

Procedural Options

• Mechanical debridement – gentle pumice stone or foot file after soaking to remove excess keratin.
• Laser therapy – CO₂ or Erbium:YAG lasers can precisely ablate thickened skin with minimal downtime.
• Phototherapy – narrow‑band UVB for associated psoriasis‑related keratoderma.

Lifestyle & Self‑Care Measures

• Regular moisturizing (preferably after hand‑washing and before bedtime).
• Avoiding harsh soaps; use fragrance‑free, pH‑balanced cleansers.
• Protective gloves for occupational exposure; cotton liners under rubber gloves to reduce sweating.
• Gentle exfoliation 1–2 times per week; avoid aggressive scrubbing.
• Use of breathable, cotton‑based socks and well‑fitting shoes; rotate footwear to allow drying.

Living with Xerosis of the Hands and Feet (keratoderma)

Managing everyday life requires a combination of skin‑care routines and practical adjustments:

• Moisturize while damp – apply ointment within 3 minutes of washing to lock in water.
• Night‑time “occlusive” therapy – cover the hands/feet with a thin cotton glove or sock after applying a thick emollient to enhance penetration.
• Foot care – inspect daily for cracks or infection; use a soft pumice stone after a warm foot bath, then moisturize.
• Hand hygiene – choose alcohol‑free sanitizers; consider barrier creams when frequent hand‑washing is required.
• Exercise & weight management – reduces pressure on the soles.
• Regular follow‑up – every 3–6 months with a dermatologist, especially when on systemic retinoids.
• Psychosocial support – visible keratoderma can affect self‑esteem; counseling or support groups may be beneficial.

Prevention

While genetic forms cannot be prevented, many secondary triggers are modifiable:

• Limit prolonged exposure to water, detergents, and solvents; use protective gloves.
• Maintain optimal skin hydration with regular emollient use.
• Treat underlying systemic diseases (e.g., diabetes, thyroid disorders) promptly.
• Keep feet clean and dry; change socks at least once daily.
• Avoid smoking and excessive alcohol, which impair skin barrier function.
• Use a humidifier in dry indoor environments during winter.

Complications

If left untreated or poorly controlled, xerosis of the hands and feet may lead to:

• Secondary bacterial or fungal infection – cellulitis, impetigo, or chronic tinea.
• Painful fissures that can limit mobility or manual tasks.
• Hyperkeratotic plaque overgrowth causing deformities or difficulty wearing shoes.
• Skin ulceration and, rarely, osteomyelitis in severe infections.
• Reduced quality of life – chronic pain, sleep disturbance, and psychosocial distress.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Keratoderma.” 2023; CDC. “Hand Hygiene in Health‑Care Settings.” 2022; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Keratoderma.” 2024; WHO. “Skin Care for the Elderly.” 2021; Cleveland Clinic Dermatology. “Palmar‑Plantar Keratoderma.” 2023; peer‑reviewed articles in Journal of the American Academy of Dermatology and British Journal of Dermatology.

```